BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19998469)

  • 1. Successful mobilization, harvest and transplant of peripheral blood stem cells using AMD3100 and G-CSF following high dose craniospinal irradiation for medulloblastoma in a young child.
    Toledano H; Yahel A; Cohen IJ; Yaniv I; Stein J
    Pediatr Blood Cancer; 2010 Apr; 54(4):613-5. PubMed ID: 19998469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegfilgrastim plus AMD 3100 for stem-cell mobilization in children.
    Cardenoux C; Deméocq F; Kanold J; Merlin E; Oudot C; Piguet C; Roussanne MC
    Pediatr Blood Cancer; 2010 Oct; 55(4):769. PubMed ID: 20806370
    [No Abstract]   [Full Text] [Related]  

  • 3. Plerixafor (Mozobil).
    Med Lett Drugs Ther; 2010 Apr; 52(1335):27-8. PubMed ID: 20360661
    [No Abstract]   [Full Text] [Related]  

  • 4. In and out of the niche: perspectives in mobilization of hematopoietic stem cells.
    Mohty M; Ho AD
    Exp Hematol; 2011 Jul; 39(7):723-9. PubMed ID: 21624427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor.
    Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y
    Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.
    Veeraputhiran M; Jain T; Cronin S; Al-Kadhimi Z; Abidi MH; Ayash L; Mellert K; Lum LG; Ratanatharathorn V; Uberti JP; Deol A
    J Clin Apher; 2014 Dec; 29(6):293-8. PubMed ID: 24700728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent.
    Cashen AF; Nervi B; DiPersio J
    Future Oncol; 2007 Feb; 3(1):19-27. PubMed ID: 17280498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
    Teipel R; Oelschlägel U; Wetzko K; Schmiedgen M; Kramer M; Rücker-Braun E; Hölig K; von Bonin M; Heidrich K; Fuchs A; Ordemann R; Kroschinsky F; Bornhäuser M; Hütter G; Schmidt H; Ehninger G; Schetelig J; Heidenreich F
    Biol Blood Marrow Transplant; 2018 Nov; 24(11):2171-2177. PubMed ID: 29935214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data.
    Calandra G; McCarty J; McGuirk J; Tricot G; Crocker SA; Badel K; Grove B; Dye A; Bridger G
    Bone Marrow Transplant; 2008 Feb; 41(4):331-8. PubMed ID: 17994119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New agents for mobilizing peripheral blood stem cells.
    Greinix HT; Worel N
    Transfus Apher Sci; 2009 Aug; 41(1):67-71. PubMed ID: 19615944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
    Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
    Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How to manage poor mobilizers for high dose chemotherapy and autologous stem cell transplantation?
    Ataca Atilla P; Bakanay Ozturk SM; Demirer T
    Transfus Apher Sci; 2017 Apr; 56(2):190-198. PubMed ID: 28034547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human progenitor cells rapidly mobilized by AMD3100 repopulate NOD/SCID mice with increased frequency in comparison to cells from the same donor mobilized by granulocyte colony stimulating factor.
    Hess DA; Bonde J; Craft TP; Wirthlin L; Hohm S; Lahey R; Todt LM; Dipersio JF; Devine SM; Nolta JA
    Biol Blood Marrow Transplant; 2007 Apr; 13(4):398-411. PubMed ID: 17382247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
    Steinberg M; Silva M
    Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
    Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
    Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plerixafor plus G-CSF in combination with chemotherapy for stem cell mobilization in a pediatric patient with Ewing's sarcoma.
    Vives S; Sancho JM; Almazán F; Juncà J; Grifols JR; Ribera JM
    J Clin Apher; 2012 Nov; 27(5):260-2. PubMed ID: 22566276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UK consensus statement on the use of plerixafor to facilitate autologous peripheral blood stem cell collection to support high-dose chemoradiotherapy for patients with malignancy.
    Douglas KW; Gilleece M; Hayden P; Hunter H; Johnson PRE; Kallmeyer C; Malladi RK; Paneesha S; Pawson R; Quinn M; Raj K; Richardson D; Robinson S; Russell N; Snowden J; Sureda A; Tholouli E; Thomson K; Watts M; Wilson KM
    J Clin Apher; 2018 Feb; 33(1):46-59. PubMed ID: 28631842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mobilization of PBSCs in poor mobilizers with POEMS syndrome using G-CSF with plerixafor.
    Shimizu N; Sakaida E; Ohwada C; Takeuchi M; Kawaguchi T; Tsukamoto S; Sakai S; Takeda Y; Sugita Y; Yokote K; Iseki T; Isose S; Kanai K; Misawa S; Kuwabara S; Nakaseko C
    Bone Marrow Transplant; 2012 Dec; 47(12):1587-8. PubMed ID: 22609884
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.